-
公开(公告)号：US20230210857A1
公开(公告)日：2023-07-06
申请号：US18088137
申请日：2022-12-23
Applicant: Enalare Therapeutics Inc.
Inventor： Joseph V. Pergolizzi , Frank Diana , Jiayi Chen , Devon E. Dodd , Isaac Agyemang
CPC classification number: A61K31/53 , A61K9/08 , A61K9/0019
Abstract: Disclosed in certain embodiments a parenteral formulation comprising a compound of Formula (I) as disclosed herein and a pharmaceutically acceptable excipient, wherein the formulation maintains at least 90% of the compound after accelerated storage conditions of 25° C. at 60% relative humidity for 2 weeks.
-
公开(公告)号：US20230140606A1
公开(公告)日：2023-05-04
申请号：US17979192
申请日：2022-11-02
Applicant: Enalare Therapeutics Inc.
Inventor： Joseph Pergolizzi , Thomas Miller , Alfred Schweikert
IPC: A61K31/519 , A61K31/53 , A61P11/00
Abstract: Disclosed in certain embodiments is a method of treating respiratory depression modulated by a non-opioid agent comprising administering, to a patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.
-
Patent Agency Ranking
公开(公告)号：US20230414624A1
公开(公告)日：2023-12-28
申请号：US18213451
申请日：2023-06-23
Applicant: Enalare Therapeutics Inc.
Inventor： Thomas Miller , Joseph V. Pergolizzi , Robert Raffa
CPC classification number: A61K31/53 , A61P11/16 , A61K45/06 , A61K9/0019
Abstract: Disclosed in certain embodiments are methods of treating neurological ventilatory insufficiency comprising administering to patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.
-
公开(公告)号：US20230310440A1
公开(公告)日：2023-10-05
申请号：US18129538
申请日：2023-03-31
Applicant: Enalare Therapeutics Inc.
Inventor： Frank Diana , Joseph V. Pergolizzi
CPC classification number: A61K31/53 , A61K9/0043 , A61K47/10 , A61K47/40 , A61K47/12
Abstract: Disclosed in certain embodiments a nasal formulation comprising a compound of Formula (I) as disclosed herein and a pharmaceutically acceptable excipient.
-
公开(公告)号：US20250032496A1
公开(公告)日：2025-01-30
申请号：US18795777
申请日：2024-08-06
Applicant: Enalare Therapeutics Inc.
Inventor： Joseph Pergolizzi , Thomas Miller , Alfred Schweikert
IPC: A61K31/519 , A61K31/53 , A61P11/00
Abstract: Disclosed in certain embodiments is a method of treating respiratory depression modulated by a non-opioid agent comprising administering, to a patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.
-
公开(公告)号：US12138267B2
公开(公告)日：2024-11-12
申请号：US17979192
申请日：2022-11-02
Applicant: Enalare Therapeutics Inc.
Inventor： Joseph Pergolizzi , Thomas Miller , Alfred Schweikert
IPC: A61K31/519 , A61K31/53 , A61P11/00
Abstract: Disclosed in certain embodiments is a method of treating respiratory depression modulated by a non-opioid agent comprising administering, to a patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.
-
公开(公告)号：US20240238303A1
公开(公告)日：2024-07-18
申请号：US18289288
申请日：2022-05-04
Applicant: ENALARE THERAPEUTICS INC.
Inventor： Robert B. RAFFA , Joseph V. PERGOLIZZI
IPC: A61K31/53 , A61K31/519 , A61K31/5355
CPC classification number: A61K31/53 , A61K31/519 , A61K31/5355
Abstract: Disclosed herein are methods of treating a disease or condition modulated by large-conductance potassium channels, the methods including administering, to a patient in need thereof, an effective amount of a large-conductance potassium channel modulating compound. Exemplary disease or conditions that may be treated include, without limitations, protection against ischemia and hypoxia at multiple points throughout the body, as well as respiration stimulation in the presence of such conditions (both local and systemic). Also described herein are pharmaceutical compositions for use in the methods of treatment of a disease or condition modulated by large-conductance potassium channels, and methods of preparing such pharmaceutical compositions.
-
-
-
-
-
-
Search Results
7
records
(took 0.012 seconds)
